Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

T-Lymphoblastic Lymphoma in a Patient with Pearson Syndrome Following Mitochondrial Augmentation

Elad Jacoby, Reut Fluss, Efrat Glick Saar, Shachar Naor, Ortal Barel, Niv Sabath, Noa Sher, Noa Greenberg-Kushnir, Bella Bielorai, Natalie Yivgi Ohana, Amos Toren, Gideon Rechavi

Blood (2024) 144 (Supplement 1): 2065.

https://doi.org/10.1182/blood-2024-199972

Published: 2024

Journal Articles

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Blood (2024) 144 (Supplement 1): 310.

https://doi.org/10.1182/blood-2024-193946

Published: 2024

Journal Articles

Long-Term Hematopoietic Dysfunction in Patients with Single Large-Scale Mitochondrial DNA Deletion Syndromes

Noa Greenberg-Kushnir, Assaf Arie Barg, Ginette Schiby, Corine Mardoukh, Nira Varda-Bloom, Diana Bar, Yair Anikster, Bella Bielorai, Amos Toren, Elad Jacoby

Blood (2023) 142 (Supplement 1): 4105.

https://doi.org/10.1182/blood-2023-182562

Published: 2023

Journal Articles

Pediatric Splenic Infarcts - a 10-Year Retrospective Study

Evgeny Grishin, Michalle Soudack, Aaron Lubetsky, Sarina Levy-Mendelovich, Omri Cohen, Amos Toren, Bella Bielorai, Gili Kenet, Assaf Arie Barg

Blood (2023) 142 (Supplement 1): 2657.

https://doi.org/10.1182/blood-2023-181079

Published: 2023

Journal Articles

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Blood (2022) 140 (Supplement 1): 8976–8978.

https://doi.org/10.1182/blood-2022-163056

Published: 2022

Journal Articles

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Blood (2022) 140 (Supplement 1): 8845–8847.

https://doi.org/10.1182/blood-2022-165954

Published: 2022

Journal Articles

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Blood (2021) 137 (12): 1582–1590.

https://doi.org/10.1182/blood.2020007848

Published: 2021

Includes: Supplemental data

Journal Articles

Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement

Elad Jacoby, MD, Sara Ghorashian, FRCPath, PhD, Britta Julia Vormoor, MD, Barbara De Moerloose, MD, Nicole Bodmer, Michael Maschan, MD, Asaf David Yanir, MD, Bella Bielorai, MD, Srdan Rogosic, Olga Molostova, MD, Claudia Rossig, Amos Toren, MD PhD, Arend von Stackelberg, MD, Jean-Pierre Bourquin, MD PhD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-141940

Published: 2020

Journal Articles

A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-134774

Published: 2020

Journal Articles

A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Blood (2019) 134 (Supplement_1): 2629.

https://doi.org/10.1182/blood-2019-122411

Published: 2019

Journal Articles

Mucormycosis Among Children with Hematological Malignancies Is Associated with High-Risk Acute Lymphoblastic Leukemia and Is Often Salvageable

Sarah Elitzur, MD, Shlomit Barzilai, MD, Assaf Arie Barg, MD, Bella Bielorai, MD, Ronit Elhasid, MD, Salvador Fischer, MD, Yariv Fruchtman, MD, Gil Gilad, MD, Shai Izraeli, MD, Mira Kharit, MD, Ruth Laor, MD, Itzhak Levy, MD, Ronit Nirel, PhD, Dror Raviv, MD, Yael Shachor-Meyouhas, MD, Isaac Yaniv, MD, Nira Arad-Cohen, MD

Blood (2018) 132 (Supplement 1): 3964.

https://doi.org/10.1182/blood-2018-99-113072

Published: 2018

Journal Articles

Characteristics and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia: Comparison Between Ethnic Populations in Israel

Ronit Elhasid, MD, Aya Abramov, MD, Nira Arad -Cohen, MD, Dina Attias, MD, Galia Avrahami, MD, Ami Ballin, MD, Myriam Ben Arush, Prof, Bella Bielorai, MD, Yoav Burstein, MD, Sara Elitzur, MD, Hertzel Gavriel, MD, Joseph Kapelushnik, Prof, Dalia Sthoeger, MD, Amos Toren, Prof, Isaac Yaniv, Prof, Michael Wientraub, MD, Ronit Nirel, MD, Shai Izraeli, Prof, Batia Stark, MD

Blood (2014) 124 (21): 2257.

https://doi.org/10.1182/blood.V124.21.2257.2257

Published: 2014

Journal Articles

Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens

Blood (2014) 123 (10): 1615–1620.

https://doi.org/10.1182/blood-2013-10-535716

Published: 2014

Journal Articles

Characteristics and Outcome of Adolescents with Acute Lymphoblastic Leukemia (ALL) Differ from Young Children in the B-Cell Lineage but Not in the T-Cell Lineage: Experience of the ALL Israeli National Studies (INS).

Ronit Elhasid, Gali Avrahami, Sr., Aya Abramov, Sr., Dina Attias, Sr., Ami Ballin, Sr., Bella Bielorai, Sr., Yoav Burstein, Sr., Herzel Gavriel, Sr., Joseph Kapelushnik, Sr., Hagit Miskin, MD, Dalia Sthoeger, Sr., MD, Michael Weintraub, Sr., Jerry Stein, Sr., Isaac Yaniv, Sr., Amos Toren, Sr., MD, PhD, Myriam Ben Arush, Sr., Ronit Nirel, Shai Izraeli, Sr., MD, B. Stark

Blood (2008) 112 (11): 902.

https://doi.org/10.1182/blood.V112.11.902.902

Published: 2008

Journal Articles

A Novel Fusion between ETV6 and NCOA2 Defines a New Entity of Acute Leukemia with Co-Expression of T-Cell and Myeloid Markers.

Sabine Strehl, Karin Nebral, Margit König, Jochen Harbott, Bella Bielorai, Stephanie Struski, Shai Izraeli, Oskar A. Haas

Blood (2006) 108 (11): 804.

https://doi.org/10.1182/blood.V108.11.804.804

Published: 2006

Journal Articles

Co-Existence of Various Sub-Clones in TEL-AML1 Positive Acute Lymphoblastic Leukemia in Association with Sub-Microscopic Deletion of AML1.

Amos Toren, MD;PhD, Rachel Rothman, Bella Bielorai, MD, Malka Reichart, Ninette Amariglio, PhD, Gideon Rechavi, MD;PhD, Luba Traktenbrot, PhD

Blood (2004) 104 (11): 1096.

https://doi.org/10.1182/blood.V104.11.1096.1096

Published: 2004

Journal Articles

Hematopoietic Stem Cells “Stemness” Genes Contain Many Genes Mutated or Abnormally Expressed in Hematopoietic Malignancies.

Amos Toren, MD, PhD, Bella Bielorai, MD, Jasmine Jacob-Hirsch, Tamar Fisher, PhD, Sharon Zelikovsky, David Givol, PhD, Eitan Domany, PhD, Joseph Itskovitz-Eldor, MD, Iris Kventsel, MD, Ester Rosenthal, Ninette Amariglio, PhD, Gideon Rechavi, MD, PhD

Blood (2004) 104 (11): 4125.

https://doi.org/10.1182/blood.V104.11.4125.4125

Published: 2004

Journal Articles

Unique SDF-1–induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling

Asaf Spiegel, Orit Kollet, Amnon Peled, Loya Abel, Arnon Nagler, Bella Bielorai, Gideon Rechavi, Josef Vormoor, Tsvee Lapidot

Blood (2004) 103 (8): 2900–2907.

https://doi.org/10.1182/blood-2003-06-1891

Published: 2004

NARROW

T-Lymphoblastic Lymphoma in a Patient with Pearson Syndrome Following Mitochondrial Augmentation

Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes

Long-Term Hematopoietic Dysfunction in Patients with Single Large-Scale Mitochondrial DNA Deletion Syndromes

Pediatric Splenic Infarcts - a 10-Year Retrospective Study

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement

A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Mucormycosis Among Children with Hematological Malignancies Is Associated with High-Risk Acute Lymphoblastic Leukemia and Is Often Salvageable

Characteristics and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia: Comparison Between Ethnic Populations in Israel

Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens

Characteristics and Outcome of Adolescents with Acute Lymphoblastic Leukemia (ALL) Differ from Young Children in the B-Cell Lineage but Not in the T-Cell Lineage: Experience of the ALL Israeli National Studies (INS).

A Novel Fusion between ETV6 and NCOA2 Defines a New Entity of Acute Leukemia with Co-Expression of T-Cell and Myeloid Markers.

Co-Existence of Various Sub-Clones in TEL-AML1 Positive Acute Lymphoblastic Leukemia in Association with Sub-Microscopic Deletion of AML1.

Hematopoietic Stem Cells “Stemness” Genes Contain Many Genes Mutated or Abnormally Expressed in Hematopoietic Malignancies.

Unique SDF-1–induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only